Thorir D. Bjornsson

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 784 citations

Medicine, Pharmacokinetics, Pharmacology +17

The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · The Journal of Clinical Pharmacology · 2003 · 309 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

Man‐Wai Lo, Michael R. Goldberg, Jacqueline B. McCrea et al. · Clinical Pharmacology & Therapeutics · 1995 · 278 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison et al. · Journal of Pharmaceutical Sciences · 2011 · 201 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies

Edward T. Hellriegel, Thorir D. Bjornsson, Walter W. Hauck · Clinical Pharmacology & Therapeutics · 1996 · 180 citations

Pharmacy, Pharmaceutics, Bioavailability +15